Price
$27.94
Increased by +0.04%
Dollar Volume (20D)
36.87 M
ADR%
0.3
Earnings Report Date (estimate)
Apr 23, 24
Shares Float
20.93 M
Shares Outstanding
63.29 M
Shares Short
1.45 M
Market Cap.
1.77 B
Beta
-2.36
Price / Earnings
66.52
20D Range
27.51 27.96
50D Range
11.74 28.15
200D Range
6.55 28.15
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Apr 23, 24 0
Increased by +100%
-0.05
Increased by +100%
Nov 16, 23 -0.37
Decreased by N/A%
-0.19
Decreased by -94.74%
Aug 9, 23 -0.35
Increased by +73.68%
-0.09
Decreased by -288.89%
May 11, 23 -0.05
Increased by +44.44%
-0.05
Mar 30, 23 -0.1
Decreased by -42.86%
-0.13
Increased by +23.08%
Nov 30, 22 0
Increased by +100%
-0.11
Increased by +100%
Aug 29, 22 -1.33
Increased by +76.75%
-0.08
Decreased by -1.56 K%
Apr 26, 22 -0.09
Increased by +35.62%
-0.09
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 53 K
Decreased by -97.64%
-22.99 M
Decreased by -73.46%
Decreased by -43.38 K%
Decreased by -7.25 K%
Jun 30, 23 1.12 M
Decreased by -13.55%
-17.83 M
Increased by +38.19%
Decreased by -1.59 K%
Increased by +28.51%
Mar 31, 23 24 K
Decreased by -97.93%
-15.3 M
Increased by +27.8%
Decreased by -63.76 K%
Decreased by -3.39 K%
Dec 31, 22 2.25 M
Increased by +93.28%
-13.25 M
Increased by +37.47%
Decreased by -590.36%
Increased by +67.65%
Sep 30, 22 2.25 M
Increased by +93.28%
-13.25 M
Increased by +32.15%
Decreased by -590.36%
Increased by +64.9%
Jun 30, 22 1.3 M
Decreased by -49.38%
-28.84 M
Decreased by -98.84%
Decreased by -2.22 K%
Decreased by -292.79%
Mar 31, 22 1.16 M
Decreased by -54.73%
-21.19 M
Decreased by -46.12%
Decreased by -1.82 K%
Decreased by -222.8%
Dec 31, 21 1.16 M
Decreased by -67.7%
-21.19 M
Decreased by -281.6%
Decreased by -1.82 K%
Decreased by -1.08 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.